<DOC>
	<DOC>NCT02987504</DOC>
	<brief_summary>This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in patients with advanced solid tumors.</brief_summary>
	<brief_title>Study of Samalizumab in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>1. Male or female patient is ≥ 18 years of age at Screening. 2. Eastern Cooperative Oncology Group performance status of 02. 3. Patient has advanced/metastatic cancer with disease progression after treatment with all available therapies known to confer clinical benefit. 4. Patient has a life expectancy of greater than 12 weeks. 1. Patient has a symptomatic brain metastasis. 2. Patient has active gastrointestinal bleeding as evidenced by either hematemesis or melena. 3. Patient has acute gastrointestinal ulcers. 4. Patient has a history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years. 5. Patient with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration. 6. Patient has an active infection requiring therapy. 7. Patient's serum is positive for the presence of hepatitis B surface antigen (HbsAg). antibodies to hepatitis C virus (HCV), or antibodies to human immunodeficiency Virus 1/2 (HIV 1/2) 8. Patient has significant cardiovascular impairment (history of New York Heart Association Functional Classification system Class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to study drug treatment. 9. The patient's most recent test values within 14 days before the date of entry meet the following standards: Bone marrow function: neutrophil count ≤ 1500/mm3, hemoglobin ≤ 9.0 g/dL, platelet count ≤ 100,000/mm3. Liver function: total bilirubin ≥ 1.5 x the upper limit of normal (ULN) based on the standard value of each institution, aspartate aminotransferase and alanine aminotransferase ≥ 2.5 x ULN based on the reference laboratory Renal function: serum creatinine ≥ 1.5 x ULN based on the reference laboratory 10. Patient has ongoing immunestimulated adverse events (AEs) from other immunotherapies (eg, pneumonitis, thyroiditis, or hepatitis) or a history of pneumonitis. 11. Patient has received chemotherapy, targeted therapy, and/or immunotherapy within the 28 days prior to first dose of study drug. 12. Patient has toxicities from previous immunotherapy that have not resolved to Grade 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Phase 1</keyword>
</DOC>